Oryzon Genomics SA (ORY) AI Stock Analysis

• Market Cap: €232.22M
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: N/A
• EPS Growth: 36.23%
• Country: ES
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 79,887,700
• 10 Day Avg. Volume: 2,474,153
• 30 Day Avg. Volume: 1,678,358
• PEG Ratio: -7.53
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 12.25
• P/FCF Ratio: -6.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.02
• Revenue Forecast (FY): €3.00M

• Rating: 48 Neutral
• Price Target: €3.00 ▼(-6.83% Downside)
• Action: Reiterated Date: 08/20/25
• Date: Action: Reiterated 08/20/25

Oryzon Genomics SA's stock score is primarily influenced by its financial performance, which shows typical growth patterns for a biotech firm but also highlights consistent losses and rising debt. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. The absence of earnings call data and corporate events means these factors do not impact the score.

Positive Factors

Strong equity position

A high equity ratio provides a durable capital buffer against clinical and development setbacks, enabling the company to sustain R&D spending and absorb operating losses longer than peers with weaker balance sheets. This stability supports long-term program continuity and partner confidence.

High gross margins

Sustained high gross margins for small-molecule therapeutics indicate scalable unit economics if programs reach commercialization. This margin profile can fund downstream activities and improve long-term profitability once development costs taper and products generate recurring revenues.

Focused epigenetics pipeline

Specialization in epigenetics creates a clear scientific niche and potential competitive advantage, concentrating expertise and IP. Clinical-stage assets reduce early-stage scientific risk relative to discovery-only peers and make the company more attractive for partnerships or licensing with strategic pharma players.

Negative Factors

Consistent net losses

Ongoing net losses and negative operating cash flow erode reserves and lengthen reliance on external capital. Over the medium term this increases dilution risk for shareholders, constrains discretionary investment, and raises execution risk if fundraising conditions tighten.

Rising leverage

An uptick in leverage reduces financial flexibility and raises fixed obligations, which can crowd out R&D spending or force cost cutting if revenues remain limited. For a clinical-stage biotech, higher debt heightens downside risk from trial delays or failures.

Reliance on external funding

Positive financing cash flows alongside persistent negative free cash flow signal ongoing dependence on capital markets. Recurrent fundraising can dilute existing holders and create execution uncertainty if access to capital weakens, impacting long-term program continuity.

Oryzon Genomics SA Business Overview & Revenue Model

Company Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

How the Company Makes Money

Oryzon Genomics SA generates revenue primarily through collaborative agreements with other pharmaceutical companies, licensing its proprietary technology, and conducting research and development projects. The company forms strategic partnerships to co-develop and commercialize its drug candidates, which may involve upfront payments, milestone payments, and royalties on future sales. Oryzon also seeks funding through government grants and research subsidies to support its ongoing R&D efforts. These partnerships and collaborations are crucial for providing the financial resources needed to advance their clinical trial programs and ultimately bring their therapeutics to market.

Oryzon Genomics SA Financial Statement Overview

Summary

Oryzon Genomics SA is experiencing typical growth and development phases for a biotech firm, with high gross margins but consistent net losses and negative cash flows. The strong equity position offers some stability, but rising debt levels and continuous losses are concerning.

Income Statement

Oryzon Genomics SA shows improving revenue presence with a significant increase from zero in 2020 to 2024, however, revenue has declined in the past year. Gross profit margins are high, but the company is operating at a net loss, impacting the net profit margin and EBIT/EBITDA margins negatively. The company appears to be focusing on growth and development, typical for the biotechnology sector, yet consistent losses are a concern.

Balance Sheet

The balance sheet indicates a strong equity position with a high equity ratio, suggesting stability. However, the debt-to-equity ratio has increased slightly, indicating rising leverage. Return on equity is currently negative due to ongoing losses. Overall, the company maintains a solid asset base, but increasing debt levels should be monitored.

Cash Flow

Cash flows reveal consistent negative free cash flow, reflecting heavy investment and operating cash outflows. The operating cash flow to net income ratio is negative due to losses. Financing activities are positive, suggesting reliance on external funding. Continuous negative cash flow is a risk, but typical for growth-focused biotech firms.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.36M	7.36M	0.00	0.00	10.62M	9.52M
Gross Profit	11.13M	7.06M	13.95M	15.23M	9.87M	8.99M
EBITDA	-1.69M	-4.43M	-4.43M	-5.35M	-6.88M	-4.16M
Net Income	-4.04M	-3.67M	-3.35M	-4.23M	-4.69M	-3.40M
Balance Sheet
Total Assets	138.35M	108.72M	106.90M	103.70M	95.38M	94.11M
Cash, Cash Equivalents and Short-Term Investments	31.11M	5.62M	12.26M	21.32M	28.72M	39.60M
Total Debt	13.73M	16.21M	13.69M	17.44M	17.52M	13.53M
Total Liabilities	24.13M	21.67M	25.13M	31.13M	24.12M	18.18M
Stockholders Equity	114.22M	87.04M	81.77M	72.57M	71.26M	75.93M
Cash Flow
Free Cash Flow	0.00	-13.40M	-15.08M	-16.12M	-15.39M	-14.04M
Operating Cash Flow	0.00	-5.69M	-574.96K	-1.85M	-3.63M	-4.82M
Investing Cash Flow	0.00	-7.81M	-14.50M	-14.27M	-11.72M	-9.08M
Financing Cash Flow	0.00	6.87M	6.02M	8.71M	4.12M	18.38M

Oryzon Genomics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Negative. The current price of 3.22 is above the 20-day moving average (MA) of 3.14, above the 50-day MA of 3.17, and above the 200-day MA of 3.01, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.95 is Neutral, neither overbought nor oversold. The STOCH value of 49.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ORY.

Oryzon Genomics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	72 Outperform	€4.21B	30.86	20.70%	1.50%	-9.39%	-25.92%
PHM	70 Outperform	€1.49B	18.42	17.22%	1.04%	7.35%	5375.64%
RJF	65 Neutral	€210.71M	47.71	2.03%	1.91%	-1.19%	-54.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORY	48 Neutral	€232.22M	-70.29	-2.87%	―	―	36.23%
ATRY	42 Neutral	€219.58M	-8.92	-9.43%	―	15.90%	37.03%